Intelligent lactose solutions
When manufacturing lactose-based excipients,
factors to be considered include'
granulation, capsule filling, direct compression
and dry-powder delivery. The range'
of innovative products from MEGGLE delivers on
all these points and more.
MEGGLE enjoys an enviable global reputation as
a'
leading pharmaceutical lactose supplier. With
its'
high-quality products and intelligent innovations,'
the organisation has achieved a prime position
in the'
manufacture of excipients. It has been active
in the market for'
more than 50 years and in that time has developed
a broad'
product portfolio that is second to none.
| |
|
| |
MEGGLE has
opened up new horizons in direct compression. |
In addition to excipients for granulation and
capsule filling,' MEGGLE provides special cutting-edge
products for direct' compression and dry-powder
inhalers. With the launch and' further development
of its compounds, the company has' opened up new
horizons in direct compression and set new' international
standards. Its clients are mainly producers of'
pharmaceutical products and nutritional supplements.
The' functionality of MEGGLE's products is also
appreciated by' other sectors, including cosmetics
and detergents.
Innovation and service
The company knows that users demand absolutely
inert'
excipients that have no activity of their own
and do not interact'
with the active substances in any other ingredients.
MEGGLE'
will meet its clients' requirements in the various
areas of'
application. These are complex demands that call
not only for'
innovative products but also for intensive consultation.'
Customers therefore have access to an experienced
team of'
experts to assist them in the development, production,'
application and refinement of excipients.
Whether MEGGLE is involved in custom manufacturing
or a'
development cooperation agreement, its objective
is always to'
share its knowledge with its partners. As a manufacturer
committed'
to innovation, MEGGLE is in constant contact with
scientific'
institutions throughout the world. This ensures
that the latest'
research findings are incorporated into its work
day after day.
MEGGLE customers can rest assured that they will
always be'
provided with state-of-the-art products and services.
To ensure'
that quality remains high for long periods, the
company pays'
particular attention to storage stability. For
example, its FlowLac'
100 has the longest storage stability of any spray-dried
lactose,'
beating all competing products by more than 50%.
Quality is king
All MEGGLE pharmaceutical lactose types comply
with the'
monograph elactose monohydrate' of the European'
Pharmacopoeia (Ph Eur). This monograph was harmonised'
between the Ph Eur, the US Pharmacopeia.National
Formulary'
and the Japanese Pharmacopoeia. The company's
sieved,'
milled, agglomerated or spray-dried lactoses and
its'
coprocessed excipients exceed all international
quality'
standards. As a result, excipients from MEGGLE
offer'
constant, reliable, cutting-edge quality.
High investment in R&D keep the organisation
one step'
ahead of the competition. All products have to
pass a series of'
strict quality tests before they are put on the
market, and the'
production process itself is subject to constant
multi-stage'
quality controls.
Products for direct compression are a particular
highlight'
of the organisation's excipient portfolio. By
coprocessing two'
different excipients, it is possible to achieve
a synergy of ideal'
characteristics that greatly simplifies and accelerates
tablet'
production. MEGGLE was one of the first manufacturers
to'
produce a coprocessed compound.
Company mission
As a leading lactose manufacturer, MEGGLE is committed'
to offering its customers throughout the world
the best'
products for their particular applications. Its
products already'
exceed international quality standards, and it
is constantly'
expanding its scope of services to maximise customer
focus.'
The company's long-term objectives are:
- maximising benefits for customers by developing'
innovative high-tech products, including products
for'
new forms of application
- expanding its leading position as an independent
producer'
in the development and improvement of excipients
- supporting customers in the development of'
new formulations
- expanding its global network of offices and
subsidiaries.'
'
'
|
